Anixa Biosciences logo
Anixa Biosciences ANIX
$ 2.58 -2.64%

Quarterly report 2025-Q4
added 03-09-2026

report update icon

Anixa Biosciences Financial Statements 2011-2026 | ANIX

Annual Financial Statements Anixa Biosciences

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

104 K 70.8 K 151 K 137 K 60.1 M 58.7 M 75.8 M 69.1 M 30.5 M 54.7 M 27 M 40.7 M 45.4 M 39.9 M 23.8 M

Shares

32.5 K 31.9 K 31 K 30.4 K 30.1 M 22.2 M 19.8 M 17.6 M 12.2 M 9.6 M 9.63 M 9.57 M 8.64 M 7.98 M 7.33 M

Historical Prices

3.19 2.22 4.87 4.52 2.97 3.07 3.28 3.94 2.36 5.4 3.01 2.75 4.75 4.5 2.75

Net Income

-10.9 M -12.6 M -9.81 M -13.6 M -13 M -10.1 M -11.6 M -14 M -5.01 M -5.02 M -1.38 M -9.61 M -10.1 M -4.25 M -7.38 M

Revenue

- - 210 K - 512 K - 250 K 1.11 M 362 K 300 K 9.26 M 3.67 M 389 K 947 K 1 M

Gross Profit

- - - - - - 83.8 K 344 K 258 K 82.6 K 5.61 M 1.68 M 72.2 K 943 K 969 K

Operating Income

-11.7 M -13.8 M -11 M -13.9 M -13.1 M -9.98 M -11.9 M -14.3 M -6.08 M -4.51 M -945 K -5.04 M -7.92 M -4.13 M -5.03 M

Interest Expense

- - - - - - - - 500 K 520 K 452 K 1.26 M 1.11 M 7.66 K -

EBITDA

-11.7 M -13.8 M -11 M -13.9 M -13.1 M -9.94 M -11.1 M -13.4 M -5.75 M -4.18 M -619 K -4.73 M -7.92 M -4.13 M -5.02 M

Operating Expenses

- - - - - 9.98 M 11.6 M 14.1 M 6.33 M 4.59 M 6.55 M 6.72 M 7.99 M 5.08 M 6 M

General and Administrative Expenses

6.63 M 7.44 M 6.29 M 7.17 M 7.07 M 5.6 M 5.66 M 6.91 M 4.41 M 2.71 M 6.23 M 6.41 M 7.99 M - -

All numbers in USD currency

Quarterly Income Statement Anixa Biosciences

2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

33.2 M 33 M 32.5 M 32.2 M 32.2 M 32.2 M 32.1 M 31.9 M 31.4 K 31.1 M 31 K 30.9 K 30.9 K 30.9 M 30.5 K 30.2 M 25.2 M 30.1 M 30.5 M 28.7 M 20.7 M 21.7 M 23.2 M 21.2 M 19.2 M 19.6 M 20.1 M 19.6 M 16.6 M 17.3 M 18.4 M 16.7 M 8.76 M 11 M 14.6 M 9.73 M 8.73 M 8.74 M 8.75 M 8.74 M 8.79 M 8.77 M 8.76 M 8.77 M 210 M 8.62 M 8.93 M 213 M 185 M 193 M 202 M 192 M 178 M 181 M 183 M 181 M - 164 M 171 M 166 M

Net Income

-2.56 M - -2.26 M -2.79 M -3.18 M - -3.28 M -3.14 M -3.26 M - -2.51 M -2.29 M -2.32 M -10.1 M -2.75 M -3.54 M -2.21 M -8.94 M -4.33 M -2.4 M -2.59 M -7.79 M -2.56 M -2.64 M -4.97 M -9.56 M -2.14 M -2.57 M -1.84 M -8.85 M -5.48 M -1.38 M -3.6 M -3.22 M -1.79 M 160 K -1.59 M -3.97 M -1.1 M -1.27 M 3.75 M -86.6 K -1.6 M -2.24 M -3.61 M -6.45 M 411 K -3.25 M -2.09 M -7.15 M -2.58 M -2.48 M -886 K -1.86 M -629 K -877 K -1.53 M -2.79 M -1.77 M -1.29 M

Revenue

- - - - - - - - - - - 210 K 513 K - - - 512 K 513 K 513 K - - - - - - 250 K 250 K 250 K - 1.11 M 362 K 750 K - 362 K 362 K - - 100 K 100 K - 9.14 M 9.26 M 95 K 25 K - 2.29 M 1.19 M 1.1 M 2.13 K - - - 449 K 350 249 K 248 K 17 K 449 K 450 K 86.9 K

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 595 K - - 2.84 M 1.09 M -

Operating Income

-2.72 M - -2.44 M -3 M -3.39 M - -3.59 M -3.47 M -3.61 M - -2.84 M -2.56 M -2.56 M -10.3 M -2.8 M -3.59 M -2.23 M -9.06 M -4.39 M -2.44 M -2.63 M -7.74 M -2.44 M -2.67 M -4.98 M -9.76 M -2.18 M -2.59 M -1.87 M -8.88 M -5.61 M -1.4 M -1.39 M -4.34 M -1.73 M -1.21 M -1.47 M -3.6 M -975 K -1.15 M 3.86 M 233 K -1.49 M -2.13 M -1.96 M -3.48 M -160 K -1.36 M -2.07 M -6.14 M -2.22 M -1.85 M -887 K -2.41 M -643 K -878 K -1.53 M -4.02 M -1.21 M -1.29 M

Interest Expense

- - - - - - - - - - - - - - - - - - - - - - 7.27 K - - 53.8 K 18.4 K - - - - - 195 K 443 K 71.7 K 176 K 124 K 383 K 132 K 127 K 109 K 334 K 116 K 109 K 379 K 1.08 M 281 K 422 K 22.2 K 983 K 125 K 835 K - - - - - - - -

EBITDA

- - - - - - - - - - - - -2.56 M -10.3 M -2.8 M -3.59 M -2.23 M -9.06 M -4.39 M -2.44 M -2.61 M -7.7 M -2.41 M -2.67 M -4.98 M -9.73 M -2.17 M -2.47 M -1.87 M -8.87 M -5.6 M -1.32 M -1.38 M -4.31 M -1.71 M -1.13 M -1.47 M -3.57 M -961 K -1.07 M 3.86 M 477 K -1.41 M -2.05 M -1.89 M -3.25 M -78.3 K -1.27 M -2.07 M -6.14 M -2.22 M -1.85 M -885 K -2.41 M -643 K -878 K -1.52 M -4.02 M -1.2 M -1.29 M

General and Administrative Expenses

1.61 M - 1.38 M 1.68 M 1.83 M - 1.67 M 1.82 M 2.26 M - 1.76 M 1.61 M 1.49 M 5.25 M 1.35 M 1.85 M 1.53 M 5.17 M 2.22 M 1.42 M 1.14 M 3.76 M 1.18 M 1.44 M 2.07 M 4.41 M 1.06 M 1.28 M 990 K 4.6 M 2.7 M 909 K 860 K 3.07 M 1.51 M 699 K 873 K 2.16 M 631 K 659 K 1.77 M 5.15 M 1.42 M 1.96 M 1.86 M 4.81 M 1.1 M 1.84 M 2.07 M 6.12 M 2.2 M 1.84 M 686 K 1.64 M 434 K 522 K 761 K 2.15 M 775 K 618 K

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Anixa Biosciences ANIX
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Anixa Biosciences plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.7 - $ 7.46 M usaUSA
Illumina Illumina
ILMN
$ 123.36 -0.78 % $ 19.6 B usaUSA
Biomerica Biomerica
BMRA
$ 2.14 -2.28 % $ 4.92 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 13.68 0.15 % $ 99.4 M israelIsrael
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Lantheus Holdings Lantheus Holdings
LNTH
$ 76.1 -0.44 % $ 5.14 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 16.23 4.64 % $ 491 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Exact Sciences Corporation Exact Sciences Corporation
EXAS
$ 104.91 - $ 19.8 B usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 4.71 2.73 % $ 436 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 8.12 2.01 % $ 1.04 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
National Research Corporation National Research Corporation
NRC
$ 17.22 -0.61 % $ 385 M usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 4.4 101.83 % $ 129 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Natera Natera
NTRA
- - $ 19.5 B usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
OPKO Health OPKO Health
OPK
- - $ 777 M usaUSA
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 156.92 2.22 % $ 7.78 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 167.86 1.07 % $ 28.9 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Personalis Personalis
PSNL
$ 7.52 3.64 % $ 446 M usaUSA
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 581.5 0.73 % $ 46.8 B usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.33 15.65 % $ 1.69 M usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 459.18 1.47 % $ 13.2 B usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 6.7 3.4 % $ 280 M usaUSA
Agilent Technologies Agilent Technologies
A
$ 112.09 0.73 % $ 34.1 B usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 101.04 1.34 % $ 8.33 B irlandaIrlanda
Sotera Health Company Sotera Health Company
SHC
$ 13.97 3.44 % $ 3.97 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 7.99 - $ 31.8 M israelIsrael
Guardant Health Guardant Health
GH
$ 85.5 0.38 % $ 10.7 B usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
$ 32.33 -2.68 % $ 1.64 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Neuronetics Neuronetics
STIM
$ 1.58 8.81 % $ 104 M usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 241.31 3.1 % $ 25.6 B schweizSchweiz
CareDx, Inc CareDx, Inc
CDNA
$ 17.57 2.45 % $ 936 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 3.38 -2.03 % $ 1.81 M usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 478.95 0.93 % $ 181 B usaUSA
Bioventus Bioventus
BVS
$ 9.05 4.75 % $ 603 M usaUSA
Celcuity Celcuity
CELC
$ 107.05 0.95 % $ 4.22 B usaUSA